Home Health News Doubt looms over hydroxychloroquine study that halted global trials – Ars Technica

Doubt looms over hydroxychloroquine study that halted global trials – Ars Technica

11 min read
15
7

The Lancet medical journal on Tuesday issued an “expression of concern” over the validity of a recent study suggesting that the anti-malarial drugs chloroquine and hydroxychloroquine raise the risk of death and heart complications in hospitalized COVID-19 patients.

More than a hundred researchers have raised questions and skepticism about the data and analysis, even as researchers halted clinical trials in light of the study’s findings.

The two drugs at the center of the controversy have had a high profile during the pandemic, with many prominent figures—most notably President Donald Trump—promoting them as effective against COVID-19. On May 18, Trump even told reporters that he was taking the drugs himself to prevent infection from the new coronavirus, SARS-CoV-2.

Despite the publicity, there’s little evidence to support the efficacy of chloroquine or its analogue, hydroxychloroquine, to prevent or treat COVID-19. Small studies done so far have only provided mixed and inconclusive results in COVID-19 patients. The two drugs are only approved for use against malaria and autoimmune diseases, such as lupus and rheumatoid arthritis. They have also long been linked to risks of heart complications.

The limited evidence for use against COVID-19 and the known risks led the Food and Drug Administration to issue a safety warning that the drugs “should be limited to clinical trial settings or for treating certain hospitalized patients.”

In the Lancet study—which was published May 22 and reported by Ars—researchers aimed to provide some clarity of the drugs’ effects in COVID-19 patients. The researchers claimed to do so using the largest set of data to date, involving more than 96,000 hospitalized COVID-19 patients from six continents. According to the authors, a thorough hashing of the data indicated that those taking either hydroxychloroquine or chloroquine had significantly higher risks of death and heart complications compared with COVID-19 patients who did not take either of the drugs.

The safety issues were concerning enough that on May 26, the World Health Organization announced that it was suspending the use of hydroxychloroquine in its global Solidarity Trial, which is evaluating several potential COVID-19 therapies. Regulators in the UK and France also changed their recommendations surrounding the drugs.

A closer look

Amid the global influence, outside researchers began closely examining the data behind the study—or at least tried to do so—and have been left concerned.

In an open letter sent to the study’s authors and The Lancet, outside experts outlined ten significant problems, ranging from inadequate statistics, data irregularities, and a lack of ethics review. The letter was signed by more than a hundred researchers.

At the heart of the problem is that the data used for the study was from a data analytics company called Surgisphere, based in Illinois. The company claims to have an enormous trove of data harvested from electronic medical records held by hundreds of hospitals around the globe. However, Surgisphere says it cannot share said data due to data use agreements it has with the hospitals.

This is problematic for critics, who are skeptical of the data the company claims to have and would very much like to see it themselves and confirm that the analysis is accurate. In the open letter, for instance, outside experts noted that:

Data from Africa indicate that nearly 25% of all COVID-19 cases and 40% of all deaths in the continent occurred in Surgisphere-associated hospitals which had sophisticated electronic patient data recording, and patient monitoring able to detect and record ‘nonsustained [at least 6 secs] or sustained ventricular tachycardia or ventricular fibrillation.’ Both the numbers of cases and deaths, and the detailed data collection, seem unlikely.

In addition to a lack of transparency over the data, a report by The Scientist magazine also noted that Surgisphere’s founder, Dr. Sapan Desai, has a less than pristine past. The magazine noted that Desai, who trained in vascular surgery and founded the company in 2008, resigned from a hospital position shortly after three medical malpractice suits were filed against him in 2019.

Further, before Desai and Surgisphere focused on data analytics, their most public-facing activity was selling medical textbooks. According to The Scientist, the textbooks had fake 5-star reviews on Amazon from accounts impersonating actual physicians. One of the impersonated physicians, a breast surgical oncologist, told the magazine that she and colleagues eventually got Amazon to remove the reviews.

For several years, Desai also published a medical journal called the Journal of Surgical Radiology, which abruptly shuttered in 2013 despite its website claiming to have accrued 50,000 subscribers in short order.

Ongoing concerns

In response to criticism and skepticism over the COVID-19 data, Surgisphere issued a statement saying, in part, that it will submit to an independent audit of its data. On May 30, some of the minor data irregularities—including a mislabeled hospital—were corrected in The Lancet.

Surgisphere wrote in its statement that it is:

[V]itally important that our scientific colleagues around the world understand the validity of our database, particularly regarding data acquisition, warehousing, analytics, and related reporting processes. We are committed to demonstrating the high standards we hold at Surgisphere, and the robustness of the work that has been completed.

Nevertheless, on Tuesday, The Lancet issued an expression of concern over the study, saying that “although an independent audit of the provenance and validity of the data has been commissioned by the authors not affiliated with Surgisphere and is ongoing, with results expected very shortly, we are issuing an Expression of Concern to alert readers to the fact that serious scientific questions have been brought to our attention. We will update this notice as soon as we have further information.”

Two other COVID-19-related studies involving Surgisphere data have also been called into question. The New England Journal of Medicine issued its own expression of concern on a Surgisphere-associated study. The research looked at the effect of preexisting use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in COVID-19 patients. Researchers have also questioned a pre-print study (one that has not yet been published or peer reviewed) looking at the anti-parasitic drug Ivermectin for COVID-19.

Let’s block ads! (Why?)


Source link

15 Comments

  1. ปั้มไลค์

    June 3, 2020 at 2:01 pm

    Like!! Really appreciate you sharing this blog post.Really thank you! Keep writing.

    Reply

  2. I really like and appreciate your blog post.

    Reply

  3. Thank you ever so for you article post.

    Reply

  4. เบอร์มงคล

    June 7, 2020 at 9:10 pm

    I like this website very much, Its a very nice office to read and incur information.

    Reply

  5. we g

    June 21, 2020 at 1:18 am

    Hi, I do think this is a great website. I stumbledupon it 😉
    I will come back once again since I saved as a favorite it.
    Money and freedom is the best way to change, may you be
    rich and continue to guide other people.

    Reply

  6. https://tinyurl.com/rsacwgxy g

    June 23, 2020 at 9:14 am

    naturally like your website however you need to check the spelling on quite a few
    of your posts. Several of them are rife with spelling issues and I to find it very troublesome to tell the truth then again I’ll
    definitely come back again.

    Reply

  7. cbd oil that works 2020

    June 29, 2020 at 9:28 am

    Hey I am so happy I found your website, I really found you by error,
    while I was researching on Bing for something else, Regardless I am here now and would just like to say
    kudos for a remarkable post and a all round thrilling blog (I also love the
    theme/design), I don’t have time to browse it all at the minute but I have bookmarked it and
    also added in your RSS feeds, so when I have time I will be back to read much more, Please do keep up the superb work.

    Reply

  8. web hosting

    July 26, 2020 at 10:51 pm

    Do you have a spam problem on this site; I also am a blogger,
    and I was wondering your situation; we have developed some nice
    practices and we are looking to trade techniques with others, why not shoot me an e-mail if interested.

    Reply

  9. Vita Stroope

    July 27, 2020 at 5:54 am

    Hello , do you want to make more money from your blog ? you can join our trusted ad network and make good daily income from your website , try our service for free and see the daily revenue how it can increased >> https://cutt.ly/adnetwork

    Reply

  10. Massachusetts CBD

    August 21, 2020 at 10:48 pm

    Hey now!

    Reply

  11. cheap flights

    August 24, 2020 at 12:36 pm

    After looking at a number of the articles on your web page, I really appreciate your way of blogging.
    I saved it to my bookmark site list and will be checking back soon.
    Take a look at my web site too and tell me your opinion. cheap flights 31muvXS

    Reply

  12. cheap flights

    August 25, 2020 at 1:50 am

    I do not even know how I stopped up right here, however I thought this submit was great.
    I don’t recognize who you might be but certainly you’re going to a well-known blogger if you aren’t already.
    Cheers! 2CSYEon cheap flights

    Reply

  13. cheap flights

    August 28, 2020 at 3:19 am

    Greetings from California! I’m bored at work so I decided to check out your blog on my iphone during lunch break.

    I enjoy the info you present here and can’t wait to take
    a look when I get home. I’m amazed at how quick your blog loaded on my mobile ..

    I’m not even using WIFI, just 3G .. Anyhow, fantastic blog!

    Reply

  14. web hosting reviews

    August 31, 2020 at 2:53 pm

    Superb blog! Do you have any tips for aspiring writers? I’m planning to start my own site
    soon but I’m a little lost on everything. Would you
    propose starting with a free platform like WordPress or go for a paid option? There are so many choices out
    there that I’m totally confused .. Any ideas? Kudos!

    Reply

  15. website hosting companies

    August 31, 2020 at 3:53 pm

    Hi it’s me, I am also visiting this web site on a regular basis, this web site is truly
    fastidious and the visitors are really sharing fastidious
    thoughts.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

Cost of another Utah Olympics rising as coronavirus adds to risks – Deseret News

SALT LAKE CITY — The price tag for hosting another Olympics in Utah is going to be higher …